


6. Stade IV / NON épidermoïde / 1<sup>ère</sup> ligne et maintenance

\*Sur échantillon tissulaire ou sur ADN circulant si échec / insuffisance - \* Hors PS>2, option pour les >70ans et PS2

Figure 12 – Arbre décisionnel pour les carcinomes non épidermoïdes de stade IV (première ligne et maintenance)



## REFERENCES

1. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. *Cancer*. 1 mai 1996;77(9):1947-55.
2. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. *J Clin Oncol Off J Am Soc Clin Oncol*. mai 1995;13(5):1221-30.
3. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer*. janv 2016;11(1):39-51.
4. Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer*. nov 2015;10(11):1515-22.
5. Cancer du poumon, Bilan initial [Internet]. INCa; 2011 juin [cité 19 déc 2014]. (Recommandations et référentiels). Disponible sur: <http://www.e-cancer.fr/publications/55-recommandations-de-pratique-clinique/516-cancer-du-poumon-bilan-initial-abrege>
6. Dietel M, Bubendorf L, Dingemans A-MC, Doooms C, Elmberger G, García RC, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. *Thorax*. févr 2016;71(2):177-84.
7. Utilisation des marqueurs tumoraux sériques dans le cancer bronchique primitif. Recommandations de la Société de Pneumologie de Langue Française. *Rev Mal Respir*. 1997;14(Suppl.3):353-39.
8. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier J-P, Varela G, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). *Eur Respir J*. juill 2009;34(1):17-41.
9. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. mai 2013;143(5 Suppl):e166S-90S.
10. Brunelli A, Varela G, Salati M, Jimenez MF, Pompili C, Novoa N, et al. Recalibration of the revised cardiac risk index in lung resection candidates. *Ann Thorac Surg*. juill 2010;90(1):199-203.
11. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. mai 2013;143(5 Suppl):e314S-40S.
12. Jeon JH, Kang CH, Kim H-S, Seong YW, Park IK, Kim YT, et al. Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: a propensity score-matched analysis. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg*. avr 2014;45(4):640-5.
13. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. *Chest*. sept 1998;114(3):675-80.
14. Thomas P, Dahan M, Riquet M, Massart G, Falcoz P-E, Brouchet L, et al. [Practical issues in the surgical treatment of non-small cell lung cancer. Recommendations from the French Society of Thoracic and Cardiovascular Surgery]. *Rev Mal Respir*. oct 2008;25(8):1031-6.
15. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. *Lancet*. 25 juill 1998;352(9124):257-63.
16. Giraud P, Lacomberie T, Mornex F. [Radiotherapy for primary lung carcinoma]. *Cancer Radiother J Soc Francaise Radiother Oncol*. sept 2016;20 Suppl:S147-156.
17. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P-J, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 1 mai 2010;28(13):2181-90.
18. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med*. 16 2017;377(20):1919-29.
19. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med*. 13 2018;379(24):2342-50.
20. Senan S, Brade A, Wang L-H, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 20 mars 2016;34(9):953-62.
21. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *J Clin Oncol Off J Am Soc Clin Oncol*. 20 janv 2007;25(3):313-8.
22. Couraud S, Souquet P-J, Paris C, Dô P, Doubre H, Pichon E, et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. *Eur Respir J*. 5 févr 2015;
23. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 31 mai 2018;378(22):2078-92.
24. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. *N Engl J Med*. 10 nov 2016;375(19):1823-33.
25. Garassino MC, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncol*. avr 2018;19(4):521-36.
26. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 10 janv 2002;346(2):92-8.
27. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 20 juill 2008;26(21):3543-51.
28. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol Off J Eur Soc Med Oncol*. sept 2016;27(suppl 5):v1-27.



29. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*. 14 déc 2006;355(24):2542-50.
30. Soria J-C, Mauguén A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. *Ann Oncol*. 1 janv 2013;24(1):20-30.
31. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol Off J Am Soc Clin Oncol*. 10 mars 2009;27(8):1227-34.
32. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol Off J Am Soc Clin Oncol*. nov 1989;7(11):1748-56.
33. Zukin M, Barrios CH, Pereira JR, Ribeiro RDA, Beato CA de M, do Nascimento YN, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. *J Clin Oncol Off J Am Soc Clin Oncol*. 10 août 2013;31(23):2849-53.
34. Quoix E, Zalcman G, Oster J-P, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. *Lancet*. 17 sept 2011;378(9796):1079-88.
35. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csösz T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 10 2016;375(19):1823-33.
36. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P, et al. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol*. 10 août 2013;31(23):2895-902.
37. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim J-H, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol Off J Am Soc Clin Oncol*. 20 août 2013;31(24):3004-11.
38. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. *Ann Oncol Off J Eur Soc Med Oncol*. mai 2014;25(5):1044-52.
39. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. *Lancet Lond Engl*. 24 oct 2009;374(9699):1432-40.
40. Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 1 oct 2012;30(28):3516-24.
41. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim J-H, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol Off J Am Soc Clin Oncol*. 20 août 2013;31(24):3004-11.
42. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 9 juill 2015;373(2):123-35.
43. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet Lond Engl*. 9 avr 2016;387(10027):1540-50.
44. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet Lond Engl*. 21 2017;389(10066):255-65.
45. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 22 oct 2015;373(17):1627-39.
46. Cortot AB. weekly paclitaxel plus bevacizumab versus Docetaxel as second or third line in advanced non squamous NSCLC: results from the phase III study IFCT-1103 ULTIMATE. ASCO 2016. (abstract 9005).
47. Zhao N, Zhang X-C, Yan H-H, Yang J-J, Wu Y-L. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. *Lung Cancer Amst Neth*. juill 2014;85(1):66-73.
48. Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J-C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. *Nat Rev Clin Oncol*. déc 2018;15(12):748-62.
49. Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. *Eur J Radiol*. juill 2015;84(7):1259-68.
50. Lee CK, Wu Y-L, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. *J Clin Oncol Off J Am Soc Clin Oncol*. 10 juin 2015;33(17):1958-65.
51. Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. *Br J Cancer*. 28 févr 2017;116(5):568-74.
52. Paz-Ares L, Tan E-H, O'Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol Off J Eur Soc Med Oncol*. 01 2017;28(2):270-7.
53. Wu Y-L, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(11):1454-66.



54. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. *J Clin Oncol Off J Am Soc Clin Oncol*. 1 août 2018;36(22):2244-50.
55. Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. *Ann Oncol Off J Eur Soc Med Oncol*. mars 2016;27(3):423-9.
56. Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. *J Clin Oncol Off J Am Soc Clin Oncol*. 2016;34(27):3248-57.
57. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 18 nov 2017;
58. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 28 août 2018;JCO2018783118.
59. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*. oct 2014;15(11):1236-44.
60. Forde PM, Ettinger DS. Managing acquired resistance in EGFR-mutated non-small cell lung cancer. *Clin Adv Hematol Oncol HO*. août 2015;13(8):528-32.
61. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med*. 16 2017;376(7):629-40.
62. Lemoine A, Couraud S, Fina F, Lantuejoul S, Lamy P-J, Denis M, et al. Recommandations du GFCO pour l'utilisation diagnostique des analyses génétiques somatiques sur l'ADN tumoral circulant. *Innov Thérapeutiques En Oncol*. 2016;2(5):225-32.
63. Goss G, Tsai C-M, Shepherd FA, Bazhenova L, Lee JS, Chang G-C, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 14 oct 2016;
64. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 31 2017;377(9):829-38.
65. Gandhi L, Ou S-HI, Shaw AT, Barlesi F, Dingemans A-MC, Kim D-W, et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. *Eur J Cancer Oxf Engl*. 1990. sept 2017;82:27-33.
66. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. déc 2016;34(34):4079-85.
67. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, et al. Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. *Ann Oncol Off J Eur Soc Med Oncol*. 1 nov 2018;29(11):2214-22.
68. Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 4 déc 2014;371(23):2167-77.
69. Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet Lond Engl*. 4 mars 2017;389(10072):917-29.
70. Cho BC, Kim D-W, Bearz A, Laurie SA, McKeage M, Borra G, et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer*. sept 2017;12(9):1357-67.
71. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. *Cancer Discov*. 2016;6(10):1118-33.
72. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol*. févr 2016;17(2):234-42.
73. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*. 26 juin 2014;370(26):2537-9.
74. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. *J Clin Oncol Off J Am Soc Clin Oncol*. 1 août 2017;35(22):2490-8.
75. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol*. déc 2017;18(12):1590-9.
76. Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han J-H, Sun J-M, et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. *Lung Cancer*. janv 2013;79(1):40-5.
77. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. *J Clin Oncol Off J Am Soc Clin Oncol*. 20 mars 2015;33(9):992-9.
78. Lim SM, Kim HR, Lee J-S, Lee KH, Lee Y-G, Min YJ, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. *J Clin Oncol Off J Am Soc Clin Oncol*. 10 août 2017;35(23):2613-8.
79. Planchard D, Besse B, Groen HJM, Souquet P-J, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol*. juill 2016;17(7):984-93.
80. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol*. mai 2016;17(5):642-50.
81. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*. oct 2017;18(10):1307-16.



82. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. sept 2015;10(9):1240-2.
83. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. sept 2015;10(9):1243-60.



## DECLARATION DES LIENS D'INTERETS

Les personnes ci-dessous ont déclaré des liens d'intérêt en oncologie thoracique pour des participations à des congrès, séminaires ou formations ; des bourses ou autre financement ; des rémunérations personnelles ; des intéressements ; ou tout autre lien pertinent dans les 3 dernières années :

ARPIN D : Takeda, Roche  
 AUDIGIER-VALETTE C : Roche, Abbvie, BMS, MSD, Takeda, Boehringer, AstraZeneca, Pfizer, Novartis, Fabre, Amgen, Lilly  
 AVRILLON V : BMS, Abbvie.  
 BARANZELLI A. : Roche, Takeda, BMS, MSD  
 BAUD M. : Boehringer  
 BAYCE BLEUEZ S. : Roche, BMS, AMGEN  
 BERARD H : Roche, Pfizer, Boehringer  
 BERNARDI M. : BMS, Sandoz, Roche  
 BOMBARON P : Roche, AstraZeneca, BMS, Boehringer.  
 COURAUD S. : AstraZeneca, Boehringer Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sysmex Innostics, Chugai, Laidet.  
 DELCLAUX B : BMS, Boehringer, AstraZeneca, Novartis, Roche.  
 DEMIR S : Pfizer, BMS  
 FALCHERO L. : Roche, Boehringer, AstraZeneca, BMS, Pfizer, Amgen.  
 FOUCHER P : AstraZeneca, Roche, BMS, MSD, Chugai, Vifor, IFCT, PFIZER  
 FOURNEL P. : Lilly, Amgen, BMS, MSD, Roche, Pfizer, Astellas, Boehringer, AstraZeneca, Takeda, Novartis, PFO  
 GERINIERE L : Lilly  
 GIAJ LEVRA M. : MSD, BMS, Roche, AstraZeneca, Novartis, Pfizer, Boehringer  
 GONZALEZ G. : Roche, Novartis, Pharmadom  
 GOUNANT V : Takeda, Lilly, Roche, AstraZeneca, BMS, Boehringer, Pfizer, Novartis.  
 GROUET A. : Boehringer, Novartis  
 HAMMOU Y : Chiesi, ISIS, Elia  
 JACOULET P : Boehringer  
 JANICOT H. Boehringer  
 LARIVE S. : TEVA Santé, Pfizer, Boehringer, BMS, MSD, AstraZeneca.  
 LE TREUT J. : AstraZeneca, Boehringer, Roche, BMS, MSD  
 LOCATELLI SANCHEZ M. : Boehringer, BMS, AstraZeneca, LFB  
 LUCIANI S : Pfizer  
 MARTIN E. : Astra Zeneca  
 MASTROIANNI B : Amgen  
 MERLE P : MSD, AstraZeneca, BMS, Pfizer  
 MORO-SIBILOT D : Roche, Pfizer, Lilly, Boehringer, MSD, BMS, Takeda, AstraZeneca, Novartis, Amgen, Abbvie  
 NAKAD A : BMS  
 ODIER L. : Lilly, Amgen, Pfizer  
 PAULUS V : MSD, Roche  
 PEROL M. : Roche, AstraZeneca, Boehringer, Lilly, Takeda, BMS, MSD, Pfizer, Novartis, Chugai  
 PERROT E. : AstraZeneca  
 PINSOLLE J. : Takeda, MSD, Roche, Pfizer, Agiradom.  
 RANCHON F : CELGENE, JAZZ PHARMA, ABBVIE  
 SAKHRI L : Pfizer, BMS.  
 SOUQUET P.-J. : Amgen, AstraZeneca, BI, CHUGAI, P FABRE, LILLY, MSD, BMS, Pfizer, Novartis, Sandoz, Roche, Takeda, Bayer, Merrimack, Merck, Astellas,  
 TAVIOT B : Chiesi  
 TISSOT C : Amgen, Sandoz, BMS  
 WATKIN E. : MSD, AstraZeneca, Boehringer, Pfizer, Roche, BMS  
 ZALCMAN G. : Roche, AstraZeneca, BMS, Pfizer, Novartis, Abbvie, MSD, Boehringer, GSK, Inventiva

Les autres participants et membres des groupes de travail n'ont déclaré aucun lien d'intérêt en oncologie thoracique. Aucun participant ou membre d'un groupe de travail n'a rapporté de lien d'intérêt avec l'industrie du tabac.





## MENTIONS LEGALES

La réunion de mise à jour des référentiels (édition 2019) a été organisée par l'Association de Recherche d'Information Scientifique et Thérapeutique en Oncologie Thoracique (ARISTOT).

Les partenaires institutionnels 2019 d'ARISTOT sont : **Amgen, Astra Zeneca, Boehringer Ingelheim, Chugai, Pfizer, Roche.**

Les référentiels en oncologie thoracique Auvergne-Rhône-Alpes® 2019 sont coordonnés et mis en forme par Sébastien Couraud (Hospices Civils de Lyon), assisté de Mme Christelle Chastand (Hospices Civils de Lyon). Ils sont édités par ARISTOT qui en est le propriétaire exclusif (y compris des versions antérieures). Ils sont diffusés à titre gratuit par le(s) partenaire(s) dûment autorisé(s) et mandaté(s) par ARISTOT. Les référentiels AURA en oncologie thoracique® est une marque déposée à l'INPI sous la référence 18 4 478 084 dont le propriétaire est l'association ARISTOT.

### Pour citer le référentiel :

Couraud S, Westeel V., Toffart A.-C, Souquet P.-J. et le comité de rédaction des référentiels Auvergne Rhône-Alpes en oncologie thoracique. Référentiel sur le cancer bronchique non à petites-cellules : actualisation 2019. ARISTOT.2019. ISBN 978-2-490858-00-2. Téléchargeable sur <http://espacecancer.sante-ra.fr/Pages/referentiels.aspx> et sur [www.lecancer.fr](http://www.lecancer.fr)

Couraud S, Westeel V., Toffart A.-C, Souquet P.-J. on behalf of the editing committee of *Auvergne Rhône-Alpes* Guidelines in Thoracic Oncology. [Guidelines on Non-Small Cells Lung Cancer : 2019 Update]. ARISTOT 2019 [French]. ISBN 978-2-490858-00-2. Available from <http://espacecancer.sante-ra.fr/Pages/referentiels.aspx> and from [www.lecancer.fr](http://www.lecancer.fr).

*L'édition 2019 du référentiel AURA en oncologie thoracique® est labellisée par:*



*L'édition 2019 du référentiel AURA en oncologie thoracique® est édité par:*



ISBN 978-2-490858-00-2

